Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||ACTR087 + SEA-BCMA|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ACTR087||ACTR-087|ACTR 087||ACTR087 is a chimeric construct consisting of the extracellular domain of CD16 linked to CD3zeta signaling and 41BB co-stimulatory domains delivered into human T-cells via gamma-retrovirus, which may lead to enhanced anti-tumor activity in combination with tumor-targeting antibodies (Blood 2016, 128(22):3512).|
|SEA-BCMA||TNFRSF17 Antibody 17||SEA-BCMA is a humanized antibody against BCMA, which may increase antibody-dependent cellular cytotoxicity and cellular phagocytosis and decrease proliferation, potentially leading to decreased tumor growth (Cancer Res July 1 2018 (78) (13 Supplement) 3833).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03266692||Phase I||ACTR087 + SEA-BCMA||Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma||Terminated||USA||0|